NCT05652673View on ClinicalTrials.gov

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2029

Conditions
Melanoma Stage IVMelanoma Stage IIIImmunotherapyToxicity, Drug
Interventions
DRUG

nivolumab

Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma

Trial Locations (1)

3015GD

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER